Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020

Author： Rogers S.L.   Perdomo C.   Friedhoff L.T.  

Publisher： Elsevier

ISSN： 0924-977X

Source： European Neuropsychopharmacology, Vol.5, Iss.3, 1995-09, pp. : 386-387

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease

By Heydorn W.E.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 10, 1997-10 ,pp. : 1527-1537

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Cholinesterase Inhibitor Treatment of Alzheimer’s Disease

By Peter Johannsen  

CNS Drugs, Vol. 18, Iss. 12, 2004-01 ,pp. : 757-768

Adis International

Access to resources Recommend Favorite

Benefits of tiotropium bromide maintained during long-term use

By  

Inpharma, Vol. 1, Iss. 1330, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Is Long-Term Treatment of Alzheimer's Disease with Cholinesterase Inhibitor Therapy Justified?

By Seltzer Ben  

Drugs & Aging, Vol. 24, Iss. 11, 2007-01 ,pp. : 881-890

Adis International

Access to resources Recommend Favorite

A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer 's Disease, in Healthy Subjects and Patients

By  

Current Clinical Pharmacology, Vol. 5, Iss. 2, 2010-05 ,pp. : 115-124

Bentham Science Publishers

Access to resources Recommend Favorite